Submission of Manuscripts
Manuscripts should be submitted online to Clarivate Analytics manuscript submission site (http://mc.manuscriptcentral.com/journals-clarivate). Manuscripts published previously in print or electronic format, or submitted for consideration elsewhere, are not acceptable. Publication of submitted manuscripts is contingent on the Editor in Chief’s approval and favorable peer review. The journal’s requirements are in accordance with the Uniform Requirements for Manuscripts Submitted to Biomedical Journals from the International Committee of Medical Journal Editors (ICMJE). Manuscripts should be submitted in Word format, typed double-spaced, preferably using Arial or Times New Roman fonts (font size 10-12), with ample margins and no right justification.
Drug monographs should include the following sections (where applicable):
Synthesis. In most cases and unless otherwise indicated, the synthesis and schemes are prepared by our chemistry department.
Summary. A brief summary (of no more than 150 words) of the main points addressed.
Background. A brief introduction covering a specific condition, target or class of agents related to the drug/biologic in question.
Preclinical Pharmacology. Summaries of in vitro and in vivo pharmacology studies.
Pharmacokinetics and Metabolism. Summaries of the preclinical and clinical data on the pharmacokinetics/metabolism.
Safety. Summaries of preclinical and clinical studies describing the toxicity and adverse events.
Clinical Studies. Summaries of clinical trials conducted, as well as mention of ongoing clinical trials (ClinicalTrials.gov).
Drug Interactions. Summaries of studies dealing with interactions or potential interactions with other drugs.
Source(s). Pharmaceutical company or companies developing the drug.
Acknowledgments/Disclosures. See below.
References. See below.
Figures and tables. Where appropriate (see below).
Review Articles and Other
Manuscripts should be logically divided into sections and subsections as appropriate and should include a summary (150-200 words) of the objectives, major points and conclusions of the article, text, acknowledgments/disclosures, references and, where appropriate, figures, tables and legends.
The title page should contain the full title and the running title of the article, the full names and affiliations of all the authors, as well as the mailing address, telephone, fax and e-mail for the corresponding author. If an author's affiliation has changed since the article was written, the new affiliation should also be listed. A Contents section including all the major section headings in the article should also be included.
Figures should be numbered in Arabic numerals in the order of their citation in the text. A legend should be included at the bottom of each figure. Figures should be sent as separate PPT, TIF or EPS files (300 dots per inch).
Tables should be numbered in Roman numerals in the order of their citation in the text. A title should be included at the top of each table and all tables should be included following the reference section.
The accuracy of all references cited is the responsibility of the author(s). The author should also verify that the same reference is not repeated. Primary sources should be cited whenever possible, and reference to unpublished data/results is generally unacceptable. The references should be parenthesized and numbered consecutively in the text. References cited only in tables or figures should be numbered after the references in the text. Journal titles should be abbreviated without periods as in PubMed. When there are 8 or more authors, use only the first 3, followed by et al. References should be cited in the Reference section (double-spaced) as follows:
1. Malinowska, K., Neuwirt, H., Cavarretta, I.T. et al. Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor. Endocr Relat Cancer 2009, 16(1): 155-69.
2. Klebanoff, S.J. Oxygen-dependent cytotoxic mechanisms of phagocytes. In: Advances in Host Defense Mechanisms, Vol. 1. Phagocytic Cells. J.I. Gaillin, A.S. Fauci (Eds.). Raven Press: New York 1982, 111-62.
3. De Pas, T., Kim, J.-H., Zarogoulidis, K. et al. MAGRIT phase III trial in adjuvant NSCLC: MAGE-A3 gene expression frequency on the first 2150 patients screened and demographics of first patients randomized. J Thorac Oncol [13th World Conf Lung Cancer (July 31-Aug 4, San Francisco) 2009] 2009, 4(9, Suppl. 1): Abst B4.3.
4. Beauregard, C., Stephens, D.J., Miller, S.T., Roberts, L., Gamache, D.A., Yanni, J.M. Comparative effects of olopatadine, bepotastine, and bilastine on conjunctival mast cell stabilization and histamine-induced vascular permeability. Annu Meet Assoc Res Vision Ophthalmol (ARVO) (April 27-May 1, Fort Lauderdale) 2008, Abst 417/A160.
Download Drugs of the Future EndNote® output style file.
Drug Names, Abbreviations and Measurements
Generic drug names according to INN (International Non-Proprietary Name) or USAN (United States Adopted Name) should be used, although trade names and code numbers may be indicated in parentheses. Abbreviations should be avoided as much as possible, should be defined the first time mentioned and should be standard. Measurements should be expressed in standard international units.
The nomenclature used for enzymes should be that established by ExPASy Proteomics Server of the Swiss Institute of Bioinformatics (http://expasy.org), although frequently used synonyms may be indicated in parentheses.
The nomenclature used for receptors and ion channels should be that established by the Committee on Receptor Nomenclature and Drug Classification of the International Union of Basic and Clinical Pharmacology (IUPHAR) (consult the GPCR Database or Ion Channels Compendium at http://www.guidetopharmacology.org/).
Genes and Proteins
Names for genes and proteins should be those established by the Human Genome Organisation (HUGO) Gene Nomenclature Committee (http://www.genenames.org) and/or those included in the UniProt Knowledgebase of the ExPASy Proteomics Server of the Swiss Institute of Bioinformatics (http://expasy.org).
Page proofs will be sent in a PDF file to the corresponding author for final corrections and approval before publication. Proofs should be returned within 48 hours of receipt unless otherwise advised.
Reprints are available by special order and a quotation may be requested by the author when returning galley proofs. For further information contact: http://support.clarivate.com
Disclosures and Acknowledgments
These sections should appear at the end of the article, before the references. They should include a list of sources of funding and support; disclosures of potential conflicts of interest (e.g., financial interests and relationships); and the names, degrees and affiliations of persons other than the authors who have made a substantial contribution to the manuscript.
Authors must not incorporate copyrighted material without written permission from the copyright holder. It is the sole responsibility of the authors to secure such permission. The fact that such permission has been granted should be acknowledged in the manuscript. Copies of letters authorizing the use of copyrighted material should be forwarded to the editor at manuscript submittal.
Drugs of the Future
Tel: +34 93 4592220
Fax: +34 93 4581535